Becton, Dickinson and Company logo

Becton, Dickinson and Company (BDX)

Market Closed
27 Jun, 20:00
NYSE NYSE
$
170. 86
+0.89
+0.52%
$
48.97B Market Cap
- P/E Ratio
3.8% Div Yield
3,070,300 Volume
- Eps
$ 169.97
Previous Close
Day Range
169.79 172.27
Year Range
163.33 251.99
Want to track BDX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 33 days
Becton, Dickinson and Company (BDX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)

Becton, Dickinson and Company (BDX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)

Becton, Dickinson and Company (NYSE:BDX ) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 2:00 PM ET Company Participants Thomas E. Polen - President, CEO & Chairman Conference Call Participants Robert Justin Marcus - JPMorgan Chase & Co, Research Division Unidentified Analyst Yes.

Seekingalpha | 2 weeks ago
Becton, Dickinson: A Dividend King Facing Challenges Offers Value

Becton, Dickinson: A Dividend King Facing Challenges Offers Value

Becton, Dickinson is significantly undervalued, trading at 12.3x earnings with a 2.5% dividend yield, the highest in a decade. The company boasts a 53-year streak of dividend growth, excellent dividend safety, and a conservative payout ratio, making it a reliable Dividend King. Despite tariff headwinds, competition, and restructuring risks, BDX's innovation, acquisitions, and organic growth support long-term revenue and EPS expansion.

Seekingalpha | 2 weeks ago
BD Stock Might See Short-term Decline After Warning on Tamponade Tubes

BD Stock Might See Short-term Decline After Warning on Tamponade Tubes

BDX warns of safety risks tied to its esophagogastric balloon tamponade tubes after one death and two injuries, prompting updated usage instructions for clinicians.

Zacks | 4 weeks ago
BD to Initiate Real-World Patient Data Registry for the Rotarexâ„¢ Atherectomy System in Treatment of Peripheral Artery Disease

BD to Initiate Real-World Patient Data Registry for the Rotarexâ„¢ Atherectomy System in Treatment of Peripheral Artery Disease

FRANKLIN LAKES, N.J. , May 28, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to initiate a patient data registry for the Rotarexâ„¢ Atherectomy System to measure real-world outcomes for patients with peripheral artery disease (PAD).

Prnewswire | 1 month ago
Cancer Patients Face Elevated Risk of Carrying Antimicrobial Resistant 'Superbugs'

Cancer Patients Face Elevated Risk of Carrying Antimicrobial Resistant 'Superbugs'

FRANKLIN LAKES, N.J. , May 21, 2025 /PRNewswire/ -- First-of-their-kind studies published in The Lancet Oncology 1 and Cancer Medicine 2 provide new data showing that cancer patients in both hospital and outpatient settings are at a substantially higher risk of developing antimicrobial resistant (AMR) infections compared to all other non-cancer patients.

Prnewswire | 1 month ago
BD Stock May Rise Following the Launch of FACSDiscover A8 Platform

BD Stock May Rise Following the Launch of FACSDiscover A8 Platform

BDX unveils the BD FACSDiscover A8, a next-gen cell analyzer with spectral flow cytometry and real-time imaging, enabling deeper insights into cell function and biology.

Zacks | 1 month ago
Becton, Dickinson and Company (BDX) Bank of America Securities Health Care Conference - (Transcript)

Becton, Dickinson and Company (BDX) Bank of America Securities Health Care Conference - (Transcript)

Becton, Dickinson and Company (NYSE:BDX ) Bank of America Securities Health Care Conference Call May 13, 2025 1:00 PM ET Company Participants Tom Polen - Chairman, Chief Executive Officer and President Conference Call Participants Travis Steed - Bank of America Securities Travis Steed [Starts Abruptly] I'm Travis Steed, Medical Device Analyst at Bank of America and I'm fortunate to have Tom Polen up next, CEO at Becton, Dickinson. So welcome.

Seekingalpha | 1 month ago
BD to Announce Financial Results for its Third Quarter of Fiscal 2025

BD to Announce Financial Results for its Third Quarter of Fiscal 2025

FRANKLIN LAKES, N.J. , May 12, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m.

Prnewswire | 1 month ago
9 Dividend Aristocrats Potentially Set To Soar, No Matter What Happens Next

9 Dividend Aristocrats Potentially Set To Soar, No Matter What Happens Next

I'm going on a 2-week vacation with my family for my sister's wedding, so I've prepared a comprehensive article with three types of dividend aristocrat recommendations for whateveriscomingnext. Low-volatility aristocrats offer a 3.4% yield, a 46% downside capture ratio, and 52% less volatility than the S&P, making them ideal for addressing recession concerns while still providing a 23% return. High-yield aristocrats offer a 7% average yield with 11%-12% long-term return potential, providing low-risk income regardless of market or economic conditions.

Seekingalpha | 1 month ago
Medical-products maker Becton Dickinson says cuts in global research funding have hurt sales

Medical-products maker Becton Dickinson says cuts in global research funding have hurt sales

Becton Dickinson & Co.'s stock fell more than 15% on Thursday toward its worst one-day loss in 26 years after the medical-products maker said global cuts in research funding are impacting its research instrument sales.

Marketwatch | 1 month ago
Becton, Dickinson and Company (BDX) Q2 2025 Earnings Call Transcript

Becton, Dickinson and Company (BDX) Q2 2025 Earnings Call Transcript

Becton, Dickinson and Company (NYSE:BDX ) Q2 2025 Results Conference Call May 1, 2025 8:00 AM ET Company Participants Greg Rodetis - Senior Vice President, Treasurer and Head of Investor Relations Tom Polen - Chairman, Chief Executive Officer and President Chris DelOrefice - Executive Vice President and Chief Financial Officer Mike Garrison - President of the Medical Mike Feld - President of the Life Sciences Rick Byrd - President of the Interventional Conference Call Participants Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan Matt Taylor - Jefferies Travis Steed - Bank of America Patrick Wood - Morgan Stanley David Roman - Goldman Sachs Matt Miksic - Barclays Operator Hello, and welcome to BD's Second Fiscal Quarter 2025 Earnings Call. At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at (800) 839-2385 for domestic calls and area code +1-402-220-7203 for international calls.

Seekingalpha | 1 month ago
Loading...
Load More